HFpEF vs HFmrEF management 🏥 via #ESC2023
🔑 Clinical Trials:
🔹DELIVER (2022) and EMPEROR-Preserved (2021): SGLT2i in EF>40%
🔹PARAGON-HF (2019): ARNI vs ARB in EF>45%
🔹TOPCAT (2014): MRA in EF>45%
🔹CHARM-Preserved (2003): ARB in EF>40%
📱App link: https://t.co/FCFC5ffric
Excellent Review article on abnormalities of septal motion: @ASE360
(1) septal flattening, (2) ASM in constrictive pericarditis, (3) septal flash, (4) ASM in preexcitation, & (5) post surgery septal motion
🔗https://t.co/DH7zEh90kL
#Cardioed#cardioTwitter#cardiology#echofirst